Our objective is to enable our partners to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves. Avillion can achieve this by incurring 100% of the clinical and regulatory risk, while advancing the development of these late-stage assets.
Currently there is significant pressure on drug development resources. Pharmaceutical and biotechnology companies need to accelerate the development of late phase drugs in the pipeline within the limits of defined R&D budgets. This together with financial pressures on the market creates a need for innovative development and finance models.